Hypofractionated, Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the safety analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ led phase III trial.
International journal of radiation oncology, biology, physics(2023)
摘要
This is the first study of moderate HF dose escalated RT in exclusively high-risk prostate cancer patients treated with long-term ADT and pelvic RT. Although our data was not analyzed as a non-inferiority, our results demonstrate that moderately HF-RT is well-tolerated and similar to SF-RT at 2 years and could be considered as an alternative to SF-RT.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要